U.S. military awarded Pfizer $ 3.5 billion to make 500 million doses of Covid-19 vaccine: Pentagon

The Pentagon reported Monday the US Army had granted Pfizer a $3.5 billion contract to produce 500 million doses of its COVID-19 vaccine before the following year’s over for dissemination all throughout the planet.

The order coordinates with the quantity of Pfizer-BioNTech vaccine doses bought by the US government under an arrangement reported last year by the Trump organization. Last month, Pfizer reported that the most recent cluster of 200 million doses would be conveyed between October of this current year and April of 2022.

In June, Pfizer and Germany-based BioNTech reported that they would give 500 million doses “at a not-revenue driven cost” to the feds for dispersion to in excess of 100 nations all throughout the planet, the vast majority of them in Africa.

“Our organization with the U.S. government will assist with bringing a huge number of doses of our vaccine to the least fortunate nations all throughout the planet as fast as could really be expected,” Pfizer Chairman and CEO Albert Bourla said at that point. “Coronavirus has affected everybody, all over, and to win the fight against this pandemic, we should guarantee facilitated admittance to vaccines for all.”

The two-shot Pfizer-BioNTech vaccine is one of three supported on a crisis premise by the Food and Drug Administration (FDA). With the quantity of COVID-19 cases flooding because of the profoundly infectious Delta variation and the inoculation rate easing back to a creep, the FDA reported last week it was reshuffling assets with an end goal to give full endorsement to the Pfizer and Moderna vaccines as fast as could really be expected.

“This will eliminate one more layer for the vaccine-reluctant,” FDA official Peter Marks told the media. “In the event that this does is get five to 10 million additional individuals immunizations down south, that will save lives.”

Last month, an investigation subsidized by Public Health England and distributed in the New England Journal of Medicine tracked down that two doses of the Pfizer-BioNTech vaccine were 88% viable at keeping extreme sickness from the Delta variation of COVID-19 and 93.7 percent viable at keeping serious ailment from the first strain of the infection.